Guangzhou Biolosion Biotechnology

Biolosion is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the discovery and development of innovative antibody therapeutics for autoimmune and inflammatory diseases. The company leverages its proprietary antibody discovery platforms to target key pathways in the type 2 immune response and Th17-mediated inflammation. Its lead candidate, BS-001, is a monoclonal antibody targeting TSLP currently in clinical development for asthma and other allergic conditions. Biolosion's pipeline also includes bispecific antibodies and next-generation biologics targeting IL-17 and IL-4Rα. The company aims to provide more effective and accessible treatment options for patients suffering from chronic inflammatory disorders globally.